SCHEMBL7188536

SCHEMBL7188536

COC(=O)C(C(=O)c1c(Cl)cccc1Cl)c1ccccc1.O=[PH3]

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.47
MMP8 P22894 1/20 0.42
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
MEN1 O00255 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ALDH1A1 P00352 2/20 0.40
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
PBRM1 Q86U86 1/20 0.39
GLS O94925 1/20 0.38
LMNA P02545 1/20 0.38
SRC P12931 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7185347 0.92 L3MBTL1 (0.43) KMT2AMMP8NPC1RAB9AMEN1
SCHEMBL7189706 0.91 FABP4 (0.44) KMT2ANPC1RAB9AMEN1SMN1; SMN2
SCHEMBL7175563 0.89 MMP8 (0.54) KMT2AMMP8NPC1RAB9AMEN1
SCHEMBL27484216 0.86 L3MBTL1 (0.43) KMT2AMMP8NPC1RAB9AMEN1
SCHEMBL7180879 0.86 NPC1 (0.39) KMT2ANPC1RAB9AMEN1SMN1; SMN2
SCHEMBL27500963 0.85 FABP4 (0.44) KMT2ANPC1RAB9AMEN1SMN1; SMN2
SCHEMBL7181234 0.85 LMNA (0.42) KMT2AMMP8NPC1RAB9AALDH1A1
SCHEMBL7186423 0.84 L3MBTL1 (0.49) KMT2AMMP8MEN1ALDH1A1PTGS1
SCHEMBL7182877 0.83 ALDH1A1 (0.44) KMT2AMMP8NPC1RAB9AMEN1
SCHEMBL7181898 0.83 ALDH1A1 (0.42) MMP8NPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 KMT2A 1586/4885MMP8 4404/4885NPC1 772/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 KMT2A 956/4885MMP8 4586/4885NPC1 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.